SCHWARZ PHARMA REPORTS DATA FROM FESOTERODINE STUDY

Schwarz Pharma has announced that data from a Phase II trial has shown fesoterodine to significantly reduce symptoms of overactive bladder syndrome.

The company said improvements were clinically relevant and seen two weeks after randomization. One hundred seventy-three patients participated in the multicenter, randomized, placebo-controlled trial and were treated with either placebo, 4 mg, 8 mg, or 12 mg of fesoterodine once daily. All three doses were shown to improve the urge to urinate and decrease the number of incontinence episodes.